Please login to the form below
biopharma
This page shows the latest biopharma news and features for those working in and with pharma, biotech and healthcare.
GSK beats expectations thanks to strong vaccine sales in Q2
Earlier this month, Elliott Management published a public letter to GSK highlighted what it perceived as ‘leadership failures’ regarding the company’s plans for the consumer health/biopharma separation as well ... In response, GSK’s board said
Latest news
-
Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
Pfizer and US biopharma company Arvinas have signed a collaboration agreement to jointly develop and commercialise an investigational oral protein degrader for breast cancer.
-
GSK supports CEO Emma Walmsley following Elliott's demands for leadership overhaul
GSK’s board said that it ‘strongly believes’ Walmsley is the ‘right leader’ for the new biopharma business. ... divisions. In response, GSK’s board said that it ‘strongly believes’ that Walmsley is the ‘right leader’ for the new
-
Bharat Biotech says its COVID-19 vaccine is 77.8% effective overall
The US-based biopharma company announced that it has also initiated discussions with Health Canada for the potential regulatory approval of its COVID-19 vaccine.
-
Elliott Management puts pressure on GSK after years of ‘disappointing performance’
Elliott added that the years of underperformance have stemmed from long-standing issues, commenting that GSK’s biopharma business is seen as ‘overly bureaucratic’. ... businesses. This would involve increasing biopharma and scientific experience
-
Pardes Biosciences, backed by Gilead and Foresite, goes public to advance lead COVID-19 antiviral drug
Early-stage biopharma company Pardes Biosciences is set to go public through a merger with special purpose acquisition company (SPAC) FS Development Corp II to advance the development of its oral
Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
GSK supports CEO Emma Walmsley following Elliott's demands for leadership overhaul
Bharat Biotech says its COVID-19 vaccine is 77.8% effective overall
Elliott Management puts pressure on GSK after years of ‘disappointing performance’
Pardes Biosciences, backed by Gilead and Foresite, goes public to advance lead COVID-19 antiviral drug
More from news
Approximately 20 fully matching, plus 460 partially matching documents found.
Latest Intelligence
-
Product launches: making the most of your one shot
All biopharma companies recognise the vital importance of the launch to a product’s success. ... Launch execution platforms like SmartLaunch allow biopharma companies to apply the same rigor and failsafe approach to launch execution as they already do
-
The new reality of building a corporate brand in pharma
According to a 2019/20 Deloitte survey, 68% of biopharma leaders said that advances in technology are one of the top five issues that will have the most impact on their
-
New thinking, bold action: building a better future for people living with severe diseases
During the height of the pandemic, we became one of the first pharmaceutical companies to participate in COVID Moonshot, a collaboration of some of the brightest minds in biopharma, academia and
-
Integrating competitive intelligence into business development, licensing and M&A strategy
One of the most profitable areas for biopharma companies to see the greatest return on their competitive intelligence (CI) investment is through its application to business development and licensing (BD&L) ... In an ever- increasing world of
-
Think fast, be different: succeeding at speed chess in 2021’s COVID-19 world
This ‘speed chess’ approach could be a winning strategy for emerging biopharma companies (EBCs). ... Emerging biopharma comes of age: advantages, but also liabilities. According to an IQVIA Clinical Development Trends Impact Assessment, EBCs account
Product launches: making the most of your one shot
The new reality of building a corporate brand in pharma
New thinking, bold action: building a better future for people living with severe diseases
Integrating competitive intelligence into business development, licensing and M&A strategy
Think fast, be different: succeeding at speed chess in 2021’s COVID-19 world
More from intelligence
Approximately 1 fully matching, plus 88 partially matching documents found.
Latest appointments
-
CureVac taps Klaus Edvardsen for chief development officer role
Edvardsen joins the German biopharma company from Merck KGaA. German biopharma company CureVac has appointed Klaus Edvardsen (pictured above) as its new chief development officer.
-
New hires at Crescendo, Healx and Galecto
Prior to joining Healx, he worked as CMO at Aparito and as therapeutic area head of orphan drugs at Mereo BioPharma.
-
New hires at FibroGen, Saniona and Turbine
Jenkins is a biopharma thought leader with over 25 years of industry experience, whose leadership roles have included global head of R&D at Merck Serono, and several senior positions at
-
New hires at Bristol-Myers Squibb, Acceleron and FerGene
While at Ipsen, Meek led a growth strategy of financial results and pipeline advancement and transformed the company into a global biopharma leader.
-
New faces at Healthware Group and HRW
ups, biopharma companies, technology firms and others. She will be based in New York City, US.
CureVac taps Klaus Edvardsen for chief development officer role
New hires at Crescendo, Healx and Galecto
New hires at FibroGen, Saniona and Turbine
New hires at Bristol-Myers Squibb, Acceleron and FerGene
New faces at Healthware Group and HRW
More from appointments
Approximately 8 fully matching, plus 143 partially matching documents found.
Latest from PMHub
-
WHITE PAPER: From bench to bedside in one year - how the race for a COVID-19 vaccine will change the future of drug development
The same can be said for the pharmaceutical industry, with experts suggesting that biopharma has progressed further in the past 10 months than in the previous 10 years. ... 13. Agrawal G, et al. The biopharma industry has shown what it can achieve when
-
COUCH Health Engages Mark Duman as Chief Strategy Officer
COUCH Health works globally with pharma, biopharma, medical device companies and CROs, providing insights, patient recruitment, patient retention, and investigator site support. ... Through our work with pharma, biopharma, medical device companies and
-
Biotech Innovation in the Time of COVID-19
Chris Garabedian, CEO of Xontogeny, dives into biotech and digital health innovation, current industry gaps and obstacles, how to encourage biotech entrepreneurs, AI &machine learning, and much more! Address:. Impetus Digital. WaterPark Place. 20
-
Welcoming analytics-driven digital marketing agency closerlook to the Fishawack Health pack
The company works with a range of innovative biopharma companies including UCB, Novo Nordisk, Astellas, Akebia, TerSera Therapeutics, Zogenix, BioMarin, and argenx. ... We are looking forward to working together to achieve our mission of better health
-
AI-Driven Customer Journey Mapping in Biopharma
Philip Poulidis (CEO &Co-founder) and Orchid Jahanshahi (VP, Life Sciences) from ODAIA explores AI and big data for customer journey mapping and dynamic segmentation, data integration, omni-channel customer engagement, and much more! Address:.
WHITE PAPER: From bench to bedside in one year - how the race for a COVID-19 vaccine will change the future of drug development
COUCH Health Engages Mark Duman as Chief Strategy Officer
More from PMHub
Approximately 2 fully matching, plus 27 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
-
Digital account director
-
Competitive
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Understanding the ‘real world’ starts and ends with the patient
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- Biogen and Eisai present new data for controversial Alzheimer's drug Aduhelm at AAIC
- Live Webinar: Making Wearable Technology Scalable and Adoptable
- Live Webinar: Transforming the Future of Health & Aging from a Global Health & Social Impact Approach
- Investors respond positively to “strong” Eli Lilly results
- Sanofi to buy mRNA tech partner, Translate Bio, for $3.2bn
- Novartis to proceed with phase 3 trial for intrathecal OAV-101 in older SMA patients
- Ask the writers: Transitioning from academia to medical writing
- Amanda Pritchard becomes NHS England’s first female chief executive
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- Resilience acquires bluebird bio’s manufacturing facility as part of cell therapy alliance
- A market-adapted agile approach to launch excellence
- Communicating for change – creating effective medical communications
PMHub
Dovetail
We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...
Latest intelligence
- Ask the writers: Transitioning from academia to medical writing
- Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
- Strategic launch planning: familiar framework, new mindset
- By James Aird...
- Guide
- How to embrace behavioural science principles in healthcare MR...
